Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TASHA M BOONE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1699745141
CMS profile
303359
Location
IRMO, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,314.41

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,307.80 143
Education $6.61 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TASHA M BOONE

NPI 1699745141 · CMS profile ID 303359

Allopathic & Osteopathic Physicians / Family Medicine

IRMO, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699745141?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TASHA M BOONE, NPI 1699745141, CMS profile ID 303359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699745141?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TASHA M BOONE, NPI 1699745141, CMS profile ID 303359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699745141?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TASHA M BOONE, NPI 1699745141, CMS profile ID 303359, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699745141?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $2,314.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $14.4103/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110079 CMS
Eisai Inc. $11.8703/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817882797 CMS
SANOFI-AVENTIS U.S. LLC $11.0503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843578925 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.1403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850349309 CMS
Amgen Inc. $16.5003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825824863 CMS
Otsuka America Pharmaceutical, Inc. $15.9503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834716367 CMS
Merck Sharp & Dohme Corporation $22.1803/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848321861 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763751292 CMS
AbbVie Inc. $16.9703/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110075 CMS
AstraZeneca Pharmaceuticals LP $13.8003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829810007 CMS
Lilly USA, LLC $28.1603/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818683649 CMS
Teva Pharmaceuticals USA, Inc. $20.5203/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839613249 CMS
AbbVie Inc. $6.2902/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110071 CMS
AstraZeneca Pharmaceuticals LP $12.7602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829358381 CMS
Teva Pharmaceuticals USA, Inc. $20.8302/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839613247 CMS
AbbVie Inc. $5.0602/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110067 CMS
SANOFI-AVENTIS U.S. LLC $11.7702/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843578901 CMS
Lilly USA, LLC $18.0502/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818683645 CMS
AbbVie Inc. $15.6302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110063 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.9202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763751294 CMS
Merck Sharp & Dohme Corporation $16.4202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848601417 CMS
Novo Nordisk Inc $22.2002/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810777155 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.9002/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850335051 CMS
Lilly USA, LLC $26.2302/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818704749 CMS
Amarin Pharma Inc. $17.1102/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815282871 CMS
AbbVie Inc. $3.6201/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110059 CMS
Forte Bio-Pharma LLC $107.8901/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796756367 CMS
AbbVie Inc. $10.5001/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110055 CMS
AbbVie Inc. $6.7601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110051 CMS
Ironwood Pharmaceuticals, Inc $19.8801/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855122511 CMS
AstraZeneca Pharmaceuticals LP $34.7501/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829961975 CMS
Teva Pharmaceuticals USA, Inc. $15.0101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839613245 CMS
AbbVie Inc. $3.7801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794110047 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.5001/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763751296 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.9101/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819870473 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5301/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763751298 CMS
Eisai Inc. $15.0801/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817806417 CMS
Amgen Inc. $22.2601/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825824859 CMS
Novo Nordisk Inc $14.5201/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811450457 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.0601/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850195445 CMS
Lilly USA, LLC $17.2901/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818764715 CMS
Otsuka America Pharmaceutical, Inc. $16.7601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834716365 CMS
SANOFI-AVENTIS U.S. LLC $18.1401/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843578875 CMS
Lilly USA, LLC $16.4001/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818683643 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,927.42 123
PY2020 $2,502.09 157
PY2021 $2,314.41 144
PY2022 $1,644.10 95
PY2023 $1,399.41 84
PY2024 $1,268.89 80
PY2025 $1,693.96 85

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $318,889.40 60
PY2024 Principal investigator $658,791.78 69
PY2023 Principal investigator $471,939.87 45
PY2022 Principal investigator $63,304.89 19
PY2021 Principal investigator $190,758.22 42
PY2020 Recipient $1,153.17 3
PY2020 Principal investigator $93,866.63 29
PY2019 Recipient $1,258.17 2
PY2019 Principal investigator $70,592.29 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $382.88 12/31/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 1202534173
Principal investigator 1 Astellas Pharma Global Development $1,826.00 12/19/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182042
Principal investigator 1 ABBVIE INC. $2,261.63 12/04/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202527852
Principal investigator 1 Astellas Pharma Global Development $913.00 11/20/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182040
Principal investigator 1 Sumitomo Pharma America, Inc. $923.40 11/19/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176655796
Principal investigator 1 Astellas Pharma Global Development $913.00 11/07/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182038
Principal investigator 1 ABBVIE INC. $299.49 11/04/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202520917
Principal investigator 1 ABBVIE INC. $4,646.79 11/04/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202520919
Principal investigator 1 Astellas Pharma Global Development $464.00 10/29/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182036
Principal investigator 1 ABBVIE INC. $300.00 10/21/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202517521
Principal investigator 1 Astellas Pharma Global Development $2,305.00 10/09/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182034
Principal investigator 1 ABBVIE INC. $5,377.04 10/08/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202513515
Principal investigator 1 Astellas Pharma Global Development $531.00 09/23/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182032
Principal investigator 1 ABBVIE INC. $1,069.14 09/03/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202508262
Principal investigator 1 ABBVIE INC. $1,778.40 08/05/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202501234
Principal investigator 1 Sumitomo Pharma America, Inc. $12,631.95 07/23/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176641123
Principal investigator 1 Genentech, Inc. $1,674.00 07/04/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579537
Principal investigator 1 Sumitomo Pharma America, Inc. $2,871.52 07/02/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176640119
Principal investigator 1 Astellas Pharma Global Development $1,779.00 06/12/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182030
Principal investigator 1 ABBVIE INC. $9,934.75 06/03/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202488349
Principal investigator 1 Astellas Pharma Global Development $1,397.00 05/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182024
Principal investigator 1 Astellas Pharma Global Development $402.00 05/22/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182026
Principal investigator 1 Astellas Pharma Global Development $1,315.00 05/15/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182028
Principal investigator 1 Genentech, Inc. $6,696.00 05/14/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579525
Principal investigator 1 Sumitomo Pharma America, Inc. $6,772.88 05/14/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176634701
Principal investigator 1 ABBVIE INC. $598.98 05/06/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202481923
Principal investigator 1 Astellas Pharma Global Development $5,193.00 04/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182008
Principal investigator 1 Astellas Pharma Global Development $2,440.00 04/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182012
Principal investigator 1 Astellas Pharma Global Development $3,062.00 04/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182018
Principal investigator 1 Astellas Pharma Global Development $440.00 04/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182022
Principal investigator 1 Genentech, Inc. $15,903.00 04/25/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579529
Principal investigator 1 Astellas Pharma Global Development $975.00 04/23/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182020
Principal investigator 1 Astellas Pharma Global Development $1,404.00 04/15/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182010
Principal investigator 1 Genentech, Inc. $2,511.00 04/09/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579533
Principal investigator 1 Astellas Pharma Global Development $1,732.00 04/08/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182016
Principal investigator 1 Sumitomo Pharma America, Inc. $175.00 04/04/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176632407
Principal investigator 1 ABBVIE INC. $2,114.53 04/03/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202473557
Principal investigator 1 Sumitomo Pharma America, Inc. $875.00 04/02/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176632077
Principal investigator 1 Astellas Pharma Global Development $3,600.00 04/01/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182014
Principal investigator 1 Genentech, Inc. $30,330.00 03/26/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579517
Principal investigator 1 Astellas Pharma Global Development $402.00 03/25/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182004
Principal investigator 1 ABBVIE INC. $300.00 03/19/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202464277
Principal investigator 1 Astellas Pharma Global Development $2,563.00 03/19/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182006
Principal investigator 1 Astellas Pharma Global Development $531.00 03/11/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182002
Principal investigator 1 ABBVIE INC. $1,412.90 03/06/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202456422
Principal investigator 1 Astellas Pharma Global Development $1,104.00 02/25/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181996
Principal investigator 1 Genentech, Inc. $23,208.00 02/21/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579514
Principal investigator 1 Genentech, Inc. $39,248.00 02/12/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579506
Principal investigator 1 Astellas Pharma Global Development $2,563.00 02/11/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234182000
Principal investigator 1 ABBVIE INC. $1,631.48 02/05/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202445731
Principal investigator 1 Astellas Pharma Global Development $2,330.00 02/05/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181998
Principal investigator 1 ABBVIE INC. $300.00 01/28/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202441668
Principal investigator 1 Genentech, Inc. $19,738.00 01/22/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579510
Principal investigator 1 Genentech, Inc. $2,648.00 01/13/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579502
Principal investigator 1 Genentech, Inc. $67,417.00 01/13/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211579521
Principal investigator 1 Sumitomo Pharma America, Inc. $6,072.64 01/08/2025 Non-covered Recipient Entity
BIOCENTRIC LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624042
Principal investigator 1 Astellas Pharma Global Development $2,139.00 01/07/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181988
Principal investigator 1 Astellas Pharma Global Development $850.00 01/07/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181990
Principal investigator 1 Astellas Pharma Global Development $2,563.00 01/07/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181992
Principal investigator 1 Astellas Pharma Global Development $1,050.00 01/07/2025 Non-covered Recipient Entity
BIOCENTRIC HEALTHCARE LLC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234181994